Introduction
Experimental allergic encephalomyelitis (EAE) is a demyelinatthe prevention of disease by the induction of oral tolerance (7, 8) . ing disease of the central nervous system that can be induced by immunization with various myelin-derived antigens, includ-A bias towards a preferential T h 1 activation and development of disease is most likely related to the presence of IL-12 ing myelin basic protein (MBP) and proteolipid protein (PLP) (1) . Much evidence has been obtained both in rats and and the relative absence of IL-4 during the early activation process. Whereas the presence of IL-12 in the microenvironmice showing that macrophages and CD4 ϩ T cells play an important role in the pathogenesis of the disease through the ment strongly favors the development of T h 1 responses (9,10), IL-4 strongly favors T h 2 development (11,12). A role for IL-12 secretion of a variety of cytokines, in particular tumor necrosis factor (TNF)-α, TNF-β and IFN-γ (2) (3) (4) . Therefore, it is assumed in the development of EAE has recently been demonstrated by showing that the treatment of mice with anti-IL-12 prevents that the disease develops in susceptible animals because of a preferential activation of T h 1 cells (5) . Indeed, it appears development of disease (13). Inhibition of EAE might be achieved by inhibition of T h 1 cells in favor of T h 2 development. that MBP-or PLP-specific T h 1 clones secreting TNF-β and IFN-γ have the capacity to transfer disease in contrast to T h 2 In addition to IL-4, one of the candidates to achieve this immune deviation might be IL-10. IL-10, originally identified clones (6) . The latter are rather involved in suppression of disease, most likely by the secretion of IL-4 and/or transby its capacity to inhibit cytokine synthesis by T h 1 clones (14), appears to act through the inhibition of IL-12 production forming growth factor-β; these cytokines are also involved in by antigen-presenting cells (15). IL-4 has been demonstrated Protein G (Pharmacia, Uppsala, Sweden) and passed through Detoxi-gel (Pierce, Rockford, IL). to prevent or inhibit disease activity in the non-obese diabetic (NOD) mouse (16), experimental arthritis (17) and EAE estabRe-induction of EAE was performed by immunization with PLP 139-151 in complete adjuvant as described above without lished by adoptive transfer (18). Suppression of macrophage activity has been suggested as one of the mechanisms of subsequent injection of B. pertussis. action (17). With regard to the effects of IL-10 in autoimmune Lymphocyte cultures diseases, contrasting effects have been described ranging from partial inhibition in rat EAE (19) to no effect in mouse EAE Lymph node cells (LNC) were isolated from inguinal and axillary lymph nodes, and suspended in RPMI 1640 containing (20) . However, in mouse EAE IL-10 limited the development of relapses induced by TNF-α (21). The recent observation that 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µM 2-mercaptoethanol, 2 mM L-glutamine and 5% (v/v) FCS (Sebak, IL-10 aggravated disease activity in an adoptive transfer model employing committed effector cells was suggestive for Aidenbach, Germany). Cells (2ϫ10 5 /well) were cultured in 96-well flat-bottom microtitre plates (Costar, Cambridge, MA) an adverse effect at a level different from T cell priming (22) . In the NOD mouse, IL-10 was found to have a beneficial and stimulated with 10 µg/ml PLP 139-151 . Cultures were terminated after 4 days by harvesting 120 µl supernatant and effect on development of disease (23). From these various studies it is, however, unclear whether IL-10 treatment affected labelling the cells for 6 h with 0.5 µCi [ 3 H]thymidine (2 Ci/ mmol; Radiochemical Center, Amersham, UK). Cells were the T h 1/T h 2 balance.
Because of the variability obtained with IL-10 in different harvested onto glass fibre filter paper (Packard, Meriden, CT). Filters were counted using a Matrix 96 β-counter in vivo studies and in view of the fact that IL-4 and IL-10 synergized in inhibiting delayed-type hypersensitivity in Leish-(Packard). This procedure has an efficiency of~20% as compared to standard liquid scintillation counting. Supermania-infected animals (24), we tested the effect of IL-10 during the induction of EAE in a comparison with IL-4 and natants from triplicate cultures were pooled and stored at -20°C for cytokine analysis. the combination of both. Our data show that in contrast to its strong polarizing effects in vitro, IL-4 does not facilitate the CD4 ϩ T cells were purified by incubation with a cocktail of two different biotinylated anti-CD4 antibodies (PharMingen, development of a strong T h 2 response during the development of EAE in the SJL mouse. Effects of cytokine treatment on the San Diego, CA), followed by incubation with streptavidinconjugated microbeads (Miltenyi Biotec, Bergisch-Gladbach, development of EAE are difficult to explain solely by modulation of the T h 1/T h 2 balance.
Germany) and separation on MiniMACS columns, according to the instructions of the manufacturer (Miltenyi). By this procedure a purity of Ͼ98% CD4 ϩ T cells was achieved.
Methods
CD4 ϩ T cells (5ϫ10 4 /well) were stimulated as described above in the presence of 2ϫ10 5 2500 rad irradiated syngeneic Induction of acute EAE and cytokine treatments spleen cells obtained from untreated animals. Female SJL/J mice were purchased from IFFA-Credo ELISA (Someren, The Netherlands) and from Jackson Laboratories (Bar Harbor, ME). At an age of 10-12 weeks, mice were IL-4 and IFN-γ were measured by ELISA employing antibodies as described previously (26) . For IL-4, antibody 11B11 (ATTC immunized with 100 µg synthetic peptide comprising amino acids 139-151 from proteolipid protein (PLP 139-151 ) dissolved HB188) was used as capture antibody and biotinylated BVD4 (kindly provided by Dr Jon Abrams, DNAX Research Institute, in 100 µl PBS and emulsified with an equal volume of complete adjuvant containing 1 mg/ml Mycobacterium tuberculosis H37 Palo Alto, CA) as detecting antibody. For IFN-γ, antibody R46A2 (ATCC HB170) was used as a capture and biotinylated Ra (Difco, Detroit, MI). After 3 days, mice were injected i.v. with 10 10 heat-inactivated Bordetella pertussis organisms AN18 (kindly provided by Dr Anne O'Garra, DNAX) as detecting antibody. ELISA plates with high binding capacity (Institute for Public Health, Bilthoven, The Netherlands). Mice developing severe signs of EAE were facilitated easy access (Greiner, Nü rtingen, Germany) were coated (overnight, 4°C) with antibodies properly diluted in 50 mM NaHCO 3 , pH 9.5. to food and water. Development of EAE was established by assessment of body weight and the disability score, according Next, plates were blocked with PBS, containing 0.05% Tween 20 and 0.2% gelatin (PTG). Incubation (overnight, 4°C) with to the following grading: 0, no symptoms; 0.5, partial loss of tail tonus; 1, complete loss of tail tonus; 2, partial paresis of cytokine-containing supernatants (eventually diluted in culture medium) was followed by washing and incubation (2 h, hind limbs; 3, complete hind limb parasesis or unilateral hind limb paralysis; 4, bilateral hind limb paralysis often 37°C) with detecting antibody, properly diluted in PTG. Plates were washed and developed after an incubation step (1 h, accompanied by incontinence; 5, death due to EAE. Mice received daily i.p. injections of human rIL-10 (2 or 20 µg, as 37°C) with streptavidin-polyHRP (CLB, Amsterdam, The Netherlands), using 3,3Ј,5,5Ј-tetramethylbenzidine (TMB; indicated) or murine rIL-4 (0.5 µg) in 200 µl PBS or PBS alone during the indicated period. Human rIL-10 (3.1ϫ10 7 U/mg) Sigma, Zwijndrecht, The Netherlands; 100 µg/ml in 0.11 M sodium acetate, pH 5.5, containing 0.003% H 2 O 2 ) as a and mouse rIL-4 (2.95ϫ10 8 U/mg) were kindly provided by Dr Satwant Narula (Schering-Plough Research Institute, substrate. After terminating the reaction with 50 µl 2 M H 2 SO 4 , plates were read at 450 nm using a BioRad Microplate reader Kenilworth, NJ). Endotoxin levels in both cytokine preparations were Ͻ0.5 IU/ml.
(BioRad, Richmond, CA). Standard curves were constructed with recombinant cytokines calibrated against DNAX standFor anti-IL-10 treatment, antibody was purified from supernatant of 2A5.1 hybridoma (25) with the use of Sepharoseards. For the measurement of antibodies directed against PLP 139-151 , plates were coated with 1 µg/ml peptide in coating buffer (50 µl/well). After blocking the plates, serum samples serially diluted in PTG were added. After incubation (overnight, 4°C), a second incubation (1 h, room temperature) was done with alkaline phosphatase-or horseradish peroxidaseconjugated goat antibodies specific for murine isotype and subclasses. With the exception of anti-IgM, anti-IgA and anti-IgG3 (Southern Biotechnology, Birmingham, AL), these reagents were from Nordic (Tilburg, The Netherlands). Pooled mouse serum with a high titre of anti-peptide antibodies was used as a standard. The concentration of antibodies (with the exception of IgA and IgE) in this standard was arbitrarily defined as 25,000 U/ml. After washing the plates, p-nitrophenyl-phosphate (1 mg/ml in 10 mM diethanolamine, 1 mM MgCl 2 , pH 9.8) was added as a substrate for alkaline phosphatase-conjugated antibodies and TMB (as described above) for peroxidase-labelled antibodies. Plates were read at 405 or 450 nm respectively. Results are expressed as units/ml.
Histology
Brain tissue and spinal cord was fixed in 10% formalin and paraffin embedded. Two representative non-serial sections per animal, each comprising four different areas of the brain tissue (brain stem, cerebellum, hemisphere and diencephalon) were analysed for infiltrates after staining with haematoxylin. The severity of the inflammatory reaction was indicated using the following histological score: 0, no infiltrates; 1, sporadic, mild perivascular infiltration (less than two inflammatory lesions per section); 2, multifocal, mild perivascular infiltration; 3, multifocal, severe perivascular infiltration; 4, multifocal, severe perivascular infiltration accompanied by spreading into the parenchyme.
Flow cytometry
LNC were incubated with various antibodies to assess the percentage of naive and memory cells. To this end we used FITC-conjugated anti-CD44 and FITC-conjugated anti-L-selectin, or anti-CD45RB in combination with mouse antirat-FITC. Alternatively, cells were stained with FITC-labelled antiCD49d (PharMingen). These antibodies were used in combination with phycoerythrin-labelled anti-CD4 (PharMingen). Previously, we have extensively demonstrated that these antibodies allow us to discriminate between naive and memory indicate the number of mice that were sacrificed for various analyses.
Results

Effect of IL-10 in the early phase of EAE induction
designed in which mice were treated daily with IL-10 starting 2 days before immunization until 5 days after immunization In view of the important role of IL-12 in the priming for T h 1-type responses and EAE, a first set of experiments was with PLP 139-151 . Figure 1 shows the development of clinical symptoms in conjunction with loss of body weight. In the PBSProlonged treatment with IL-10 inhibits EAE development; IL-4 is ineffective treated animals, the first clinical symptoms usually appeared around day 11 (mean day of onset 11.3 Ϯ 1.2), whereas the It might be that treatment with IL-10 from day -2 until day 5 peak of disease activity was found around day 16. Treatment causes an accumulation of differentiating CD4 ϩ T cells in an with 2 µg IL-10 or 20 µg IL-10 did not affect the incidence of intermediate T h 0-like stage, in which cells still have the disease which appeared at 100% in all experimental groups.
capacity to differentiate into T h 1 cells with a delay only. However, a delay in onset of disease was observed in the Therefore, we tested whether prolonged treatment with 2 group of mice, daily treated with 2 µg IL-10 (mean day of µg IL-10 would result in inhibition of EAE. Because of its onset: 14.3 Ϯ 3.2; P Ͻ 0.0001) or 20 µg IL-10 (mean day of exacerbating effect 20 µg IL-10 was not further studied. IL-10 onset: 14.2 Ϯ 2.1; P Ͻ 0.0005). No significant effect was was compared with IL-4 which has been demonstrated to be found on the severity of disease: the means of the maximal effective in inhibiting EAE after adoptive transfer (18), as well clinical scores were 3.0 Ϯ 1.2 for mice receiving PBS, 2.4 Ϯ as in inhibiting the development of diabetes in NOD mice (16). 1.3 for mice treated with 2 µg IL-10 and 3.8 Ϯ 1.5 for mice
As shown in Table 1 and in Fig. 2 (top panels), treatment treated with 20 µg IL-10. This is also reflected in the mean with IL-10 from day 0 until day 12 significantly inhibited onset clinical scores for each day as shown in Fig. 1 . In the group of disease by 6 days and caused a 2-fold decrease in severity of mice treated with 20 µg IL-10 the severity of disease was of disease. This was evident from a lower incidence, a rather increased, given the higher mortality as a consequence decrease in the mean maximal clinical score (P ϭ 0.0002) of the disease (indicated in Fig. 1 with a 'ϩ' for each animal) .
and a lower mortality (P Ͻ 0.001). By contrast, treatment with We did not obtain evidence for a role of endogenous IL-10 IL-4 did not affect the development of disease (Table 1 and as a regulator of the onset of disease, since treatment of mice Fig. 2 , lower left). with anti-IL-10 (1 mg antibody i.p. on day -2, day 0 and day It has been demonstrated that IL-4 and IL-10 synergize in inhibiting delayed-type hypersensitivity responses in cutane-3) had no effect on the mean day of onset (data not shown). a Mice (n ϭ 6) were daily injected (i.p.) with PBS or 2 µg IL-10 from day 0 until day 12. EAE was induced on day 0 and re-induced on day 108, as described in Methods.
b Mortality two out of six mice. c Mortality one out of four mice. Fig. 4 . IL-4 treatment in contrast to IL-10 treatment inhibits PLP 139-brain tissue. The severity of the inflammatory response was expressed 151 -specific IFN-γ production. LNC were isolated from individual mice, on a scale of 0 (no infiltrates) to 4 (severe inflammatory response) as subjected to EAE induction and cytokine treatment, at the peak of indicated in Methods. Each symbol represents one individual mouse. disease activity (day 14-17) and re-stimulated in vitro with PLP 139-ous Leishmaniasis (24). We therefore investigated whether IL-4 would enhance the inhibitory effect of IL-10 on EAE. However, as shown in Table 1 and Fig. 2 (lower right), IL-4 activity by potentiating the release of inflammatory mediators by for instance macrophages rather than by enhancement of rather abrogated the effect of IL-10 on EAE development (IL-10 versus IL-4 ϩ IL-10, P Ͻ 0.001). Moreover, our data the number and size of the infiltrates was not addressed. were suggestive of a slower recovery under these conditions.
Fig. 3. Effect of cytokine treatment on the inflammatory response in
Cytokine treatment does not result in the development of To establish whether the effects of cytokine treatment on down-regulatory T h 2 cells the development of EAE were consistent with an effect on the inflammatory response, brain tissues from treated mice were
To establish whether the effect of IL-10 was related to a less effective priming of T cells we examined whether these mice analysed on day 14, at the peak of disease activity, with respect to the severity of the inflammatory response. The contained a lower fraction of CD4 ϩ T cells, characterized by the absence of L-selectin and CD45RB and/or an increased results are depicted in Fig. 3 . The results were largely consistent with the effects of cytokines on clinical symptoms, expression of CD44 and CD49d. However, this appeared not to be the case (data not shown). i.e. IL-10 inhibited the inflammatory response in brain tissue, whereas IL-4 had no effect. The difference between IL-10-We next investigated whether cytokine treatment affected the ability of LNC to produce IFN-γ and IL-4. To this end, LNC treated mice and IL-4-treated mice was statistically significant (P Ͻ 0.05). Surprisingly, IL-4 was incapable to prevent IL-10 from treated mice were isolated at the peak of disease activity and re-stimulated in vitro with PLP 139-151 . As shown in Fig. 4 , from its inhibitory effect on inflammation in brain tissue ( Fig.  1 ; IL-10 versus IL-4 ϩ IL-10, P ϭ 0.84; IL-4 versus IL-4 ϩ LNC from IL-10-treated mice were only slightly less capable of responding to the peptide than LNC from untreated mice, IL-10, P Ͻ 0.01). The possibility that IL-4 aggravates disease composition of antibodies of IL-4 ϩ IL-10-treated mice versus PBS-treated mice.
Peptide-specific IgM was slightly lower in IL-4-treated mice (P ϭ 0.09); IgA and IgE were undetectable in all sera tested.
The effects of cytokine treatment on the T h 1/T h 2 balance are depicted in Fig. 7 , using IgG1 and IgG2a as a read-out for the in vivo activity of T h 2 and T h 1 cells respectively. Whereas IL-10 treatment mediated a shift to T h 2, IL-4-treated mice were inhibited both at the level of T h 1 and T h 2 cells. Fig. 5 . IL-4 treatment inhibits the production of antibodies specific for PLP [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] . Sera from individual mice were collected at the peak of disease activity (day 14-17) when mice were sacrificed. Antibody Discussion titres were measured by ELISA, using pooled serum of EAE mice as a standard. Titres are arbitrarily expressed in U/ml. Each symbol A T h 1/T h 2 disbalance is assumed to be one of the precipitating represents one individual mouse. factors in the development or re-activation of autoimmunity, allergy and infectious diseases. In the present study we show that modulation of EAE by cytokine treatment is not merely a reflection of modulation at the level of IFN-γ. IL-4 treatment, as measured by a lower production of IFN-γ. By contrast, causing a strong inhibition of IFN-γ production by LNC, was in vivo treatment with IL-4 significantly inhibited the secretion ineffective in inhibiting disease, whereas IL-10 treatment, of IFN-γ by LNC (P Ͻ 0.005) in response to PLP [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] .
which was less effective in inhibition of IFN-γ production by Simultaneous treatment with IL-4 and IL-10 did not affect the LNC, clearly inhibited EAE. Both cytokine treatments inhibited IFN-γ production. In all experimental groups IL-4 production the formation of IgG2a antibodies, a read-out in vivo for the remained below the detection limit of 4 pg/ml (data not activity of T h 1 cells. Since we observed that CD4 ϩ T cells shown). Two experiments in which CD4 ϩ T cells were purified from IL-10-treated mice as well as from IL-4-treated mice from pooled LNC from cytokine-treated groups revealed only were inhibited in terms of IFN-γ production (data not shown), low levels of peptide-specific IL-4 (4-20 pg/ml, being the it is likely that IL-10 inhibited T h 1 cells only and that IL-4 highest in the PBS-treated animals) without evidence for an inhibited IFN-γ production by other cells as well. Such IFN-γ up-regulation of IL-4 in the groups that developed less severe production may come from NK cells and/or CD8 ϩ T cells, in disease (data not shown).
response to peptide and/or peptide-induced IL-2. Possibly, When PBS-treated and IL-10-treated mice, recovered from IFN-γ production by these cells is needed to limit the severity the first phase of disease activity, were subjected to reof EAE. induction of EAE on day 108 it appeared that both experi-
The possibility that IFN-γ plays a dual role in the immunomental groups were equally sensitive to the development of pathogenesis of EAE is in line with observations showing that new symptoms (Table 2) . It is therefore likely that IL-10 anti-IFN-γ renders resistant mouse strains susceptible to EAE treatment is not capable of facilitating the development of (29, 30) . In addition, it was demonstrated recently that IFN-γ sufficient antigen-specific T h 2 cells to allow long-lasting resistknockout mice remain susceptible to EAE induction (31) ance in this model. and that a defective IFN-γ production even abrogates EAE resistance of BALB/c mice (32) . Moreover, it is known from Effects of IL-4 and IL-10 treatment on the primary antibody studies in the rat that IFN-γ directly inhibits EAE when applied response to PLP [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] locally (33) . Further experiments regarding the contribution A possible explanation for the finding that IL-4 counteracted of IFN-γ coming from CD4 ϩ T cells, CD8 ϩ T cells and NK IL-10 in inhibiting EAE might be that IL-4-whether or not in cells to different stages of the immunopathogenesis of EAE conjunction with IL-10-induced a strong humoral response are needed for a full understanding of an eventual dual role which in turn could accelerate the pathogenesis of the disof IFN-γ. ease. We therefore studied the production of antibodies
In neither of the in vivo cytokine treatments were we able directed against the synthetic peptide. As shown in Fig. 5 for to demonstrate the up-regulation of a T h 2 response in vitro total Ig directed against PLP 139-151 , IL-4 significantly inhibited when cells were analysed at, or shortly after, the peak of the production of such antibodies. IL-10 alone or in combinadisease activity. In one experiment, CD4 ϩ T cells were anation with IL-4 had no effect in this regard.
lysed on day 38 when mice had recovered from disease; Since T h 1 and T h 2 cells preferentially induce the production peptide-specific IL-4 production was relatively high (124 pg/ of IgG2a and IgG1 antibodies respectively, we studied the ml) in the PBS group but lower (50 pg/ml or less) in the isotype and subclass of the anti-PLP antibodies.
cytokine-treated groups (data not shown). We were therefore As shown in Fig. 6 , IL-10-treated mice showed less peptideunable to obtain formal proof for the induction of T h 2 cells by specific IgG2a (P Ͻ 0.02) and IgG3 (P Ͻ 0.05), and more cytokine treatment in our experiments. IgG1 (P Ͻ 0.05). This altered composition of antibodies is It has been demonstrated that SJL mice are impaired in suggestive for a shift to a T h 2 type of response. In IL-4-treated the production of IgE and that this might be related to the mice, the concentrations of IgG1 (P Ͻ 0.05), IgG2a (P Ͻ absence of NK1.1 ϩ CD4 ϩ T cells which form the first source 0.02), IgG2b (P Ͻ 0.05) and IgG3 (P Ͻ 0.05) were all lower of IL-4 and are hence regarded as being crucial for the as compared to PBS-treated mice. IL-4 again abrogated the development of T h 2 cells (34). On the other hand, it has been shown more recently in different mouse strains that these effect of IL-10 since no differences were found in the antibody influence of sex hormones is expected to be absent (data not shown). Due to such complex interactions with hormone systems in vivo it cannot be fully excluded that lower amounts of IL-4 would have been more effective.
The only evidence for an effect of cytokine treatment on the induction of a T h 2 response was obtained in IL-10-treated mice where inhibition of the IgG2a response was accompanied by an increase in IgG1. However, since IL-10-treated mice that had recovered from disease were equally sensitive to re-induction of disease compared to untreated mice, it is likely that the contribution of such T h 2 cells to important effect of IL-10 is at the level of the central nervous system where it might act by inhibiting macrophages and glial cells on the level of secretion of TNF-α, NO synthase or NK1.1 ϩ T cells are dispensable for the induction of T h 2 proteolytic enzymes. The relevance of a local effect of IL-10 responses (35, 36) . Accordingly, we would have expected is substantiated by the observation that IL-10 mRNA is upthat the need for such early IL-4 would have been substituted regulated in brain tissue during the recovery phase of the by systemic treatment with IL-4. However, treatment with disease (38). A possible effector mechanism of IL-10 may amounts of IL-4 that were close to effective doses in other also be the inhibition of vascular permeability (39). in vivo models, i.e. the NOD mouse and adoptively transferred Since IL-4 strongly inhibited the immune response without EAE, appeared ineffective. On the basis of IL-4 production preference for T h 1 or T h 2 cells, and this did not result in in vitro and using the production of IgG1 as an in vivo readinhibition of the inflammatory response in brain tissue, it might out, IL-4 treatment did not result in up-regulation of T h 2 cells also be that local effects are explanatory for the fact that IL-4 but rather inhibited the T h 2 response. Possibly, the inability does not inhibit EAE. Because IL-4 and TNF-α have previously of these mice to generate a detectable T h 2 response even in been shown to induce VCAM-1 on endothelial cells in vitro the presence of IL-4 is related to the suppressive activity of (40) and because treatment of mice with anti-CD49d inhibited sex hormones, since it has been demonstrated by Cua et al.
EAE (41), we addressed the possibility that IL-4 may deterior-(37) that male SJL mice in contrast to female SJL mice mount ate EAE by acting on this level. However, the in vivo cytokine a significant T h 2 response which renders male mice resistant treatments did not affect CD49d expression on CD4 ϩ T cells; to EAE. This possibility is supported by our observation that with regard to VCAM-1 expression in brain tissue, the only CD4 ϩ T cells from unimmunized female SJL mice are well consistent observation was inhibition of expression in mice able to respond to anti-CD3 with significant IL-4 production treated with both IL-10 and IL-4 (data not shown). The possibility that IL-4 up-regulates local expression of chemoand development of T h 2 cells in vitro, conditions where the 
